Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease [5]

Journal of Neurology

Volumn 254, Issue 11, 2007, Pages 1604-1606

  Chan, A ^a,b   Lee, D H ^a,b   Linker, R ^a,b   Mohr, A ^a   Toyka, K V ^c   Gold, R ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADULT; B LYMPHOCYTE; CASE REPORT; CYTOTOXICITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOLOGY; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROIMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIBODIES; ANTIGENS, CD20; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 36348975152     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-0593-9     Document Type: Letter

References (11)

1. Martin F, Chan AC (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24:467-496
2. Meinl E, Krumbholz M, Hohlfeld R (2006) B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 59:880-892
3. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115-121
4. Keegan M, König F, McClelland R, Brück W, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Multiple sclerosis pathological subtype predicts treatment response to therapeutic plasma exchange. Lancet 366:579-582
5. Flachenecker P, Taleghani BM, Gold R, Grossmann R, Wiebecke D, Toyka KV (1998) Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus Sci 19 (Suppl):43-46
6. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316-1321
7. Stuve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, Kieseier BC (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62:1620-1623
8. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
9. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62:258-264
10. Heininger K, Hendricks M, Toyka KV, Kolb H (1983) Myasthenia gravis: remission not induced by blocking anti-idiotype antibodies. Muscle Nerve 6:386-387
11. (2006) www fda gov/cder/drug/InfoSheets/HCP/rituximab pdf